Gold Standard Diagnostics, a Eurofins Technologies Company, Launches CE Marked Assay for the Detection of the Omicron SARS-CoV-2 Variant
14 Décembre 2021 - 9:00AM
Business Wire
Gold Standard Diagnostics continues its response to the threat
of the emerging Omicron SARS-CoV-2 variant by providing innovative
diagnostic solutions.
The Omicron SARS-CoV-2 variant has raised significant concerns
given its rapid spread in South Africa and has now been confirmed
in over 40 countries. The variant contains many mutations which may
enable the virus to evade the immune response raised by previous
infection or vaccination.
With the current uncertainty surrounding the dangers of the
Omicron SARS-CoV-2 variant, it is crucial to closely monitor its
spread and provide reliable diagnostic solutions for its
identification. By now, the variant has already split in two
sublineages (BA.1 & BA.2) one of which, nicknamed the ‘stealth
Omicron’, does not carry the Spike protein deletion 69/70. This
deletion, however, has so far been used as a workaround to identify
this variant through a dropout in a widely used RT-PCR assay
[1].
Gold Standard Diagnostics Europe now offers a rapid and reliable
RT-PCR assay detecting Omicron SARS-CoV-2 variant, including both
sublineages. GSD NovaType II SARS-CoV-2 specifically identifies
mutations N501Y and K417N, present in Omicron in approximately 1
hour, much faster than genome sequencing methods. The assay is
CE-marked and available immediately.
GSD NovaType II SARS-CoV-2 supplements the product range
developed in response to emerging SARS-CoV-2 variants, such as GSD
NovaType Detect & Select K417N SARS-CoV-2 (RUO), that combines
SARS-CoV-2 detection and identification of an Omicron signature
mutation in one reaction.
Reference [1]
https://github.com/cov-lineages/pango-designation/issues/361
For more information, please visit Eurofins Technologies
website.
About Eurofins Technologies – a fast growing provider of
diagnostic technologies in the field of immunoassays and molecular
detection methods
Building on the experience and scientific excellence of the
Eurofins Group, Eurofins Technologies is a fast-growing global
provider of diagnostic technologies and industry-leading
ELISA-based instruments in the field of bioanalytical testing for
the food, feed, environmental, animal health, and clinical
diagnostics industries.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network
of 900 laboratories in over 50 countries, Eurofins’ companies offer
a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211214005150/en/
For further information: Rodrigo Berlie
ir@eurofins.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024